MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences Feb 9, 2024 08:05AM
MaxCyte (MXCT) and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline Jan 3, 2024 08:05AM
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline Jan 3, 2024 08:05AM
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance Aug 9, 2023 04:05PM
MaxCyte (MXCT) Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients Aug 1, 2023 08:07AM


Aug 1, 2023 08:05AM MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
Jul 13, 2023 08:05AM MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
Jul 6, 2023 08:06AM MaxCyte (MXCT) Enters Strategic Platform License with Lyell Immunopharma
Jul 6, 2023 08:05AM MaxCyte Signs Strategic Platform License with Lyell Immunopharma
May 4, 2023 08:07AM MaxCyte (MXCT) Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
May 4, 2023 08:05AM MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
Apr 12, 2023 04:05PM MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
Mar 27, 2023 04:05PM MaxCyte, Inc. (MXCT) Appoints Douglas Swirsky as CFO
Mar 27, 2023 04:05PM MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
Mar 8, 2023 08:00AM MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
Jan 3, 2023 04:06PM MaxCyte (MXCT) Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
Jan 3, 2023 04:05PM MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
Dec 5, 2022 02:00AM MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
Sep 21, 2022 08:05AM MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor